Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

The Association between Polymorphisms in the CYP17 and 5α-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men

Naomi E. Allen, Matthew S. Forrest and Timothy J. Key
Naomi E. Allen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew S. Forrest
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy J. Key
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published March 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    Adjusteda mean hormone concentrations by CYP17 MspA1 I and SRD5A2 V89L polymorphisms in 622 British men

    CYP17 geneSRD5A2 gene
    A1/A1 n = 266A1/A2n = 273A2/A2n = 83PbV/Vn = 317V/Ln = 245L/Ln = 49Pb
    Testosterone (nmol/liter)20.2 (19.4–21.1)21.0 (20.1–21.9)20.6 (19.1–22.2)0.44621.2 (20.4–22.0)c20.2 (19.4–21.1)18.7 (16.8–20.6)c0.037
    FT (nmol/liter)0.43 (0.41–0.44)0.43 (0.42–0.45)0.42 (0.39–0.44)0.4770.44 (0.42–0.45)d0.43 (0.42–0.45)c0.37 (0.34–0.40)d,e0.001
    A-diol-g (nmol/liter)8.90 (8.46–9.36)8.74 (8.31–9.19)8.13 (7.36–8.93)0.2568.82 (8.41–9.24)8.74 (8.27–9.21)7.96 (6.99–9.00)0.313
    SHBG (nmol/liter)44.3 (42.1–46.7)46.3 (44.0–48.7)49.3 (45.0–54.2)0.12846.6 (44.5–48.9)44.3 (42.0–46.7)c50.7 (45.0–57.1)e0.093
    LH (IU/liter)5.34 (5.04–5.66)5.06 (4.79–5.36)5.50 (4.96–6.10)0.2665.39 (5.11–5.68)5.29 (4.98–5.62)5.16 (4.51–5.91)0.809
    • a Values are adjusted for age (in categories of 20–29, 30–39, 40–49, 50–59, 60–69, 70+), time of day at venipuncture (<10, 10–13.29, 13.30+ h), time since last meal at venipuncture (<1.5, 1.5–<3, 3+ h), and time between blood draw and processing (1, 2, 3, 4+ days).

    • b P is test for heterogeneity across the mean hormone concentrations in each genotype (see text).

    • c Test of heterogeneity between two means; where two superscripts are the same, V/V genotype is different from V/L genotype at P < 0.05.

    • d Test of heterogeneity between two means; where two superscripts are the same, V/V genotype is different from L/L genotype at P < 0.05.

    • e Test of heterogeneity between two means; where two superscripts are the same, V/L genotype is different from L/L genotype at P < 0.05.

PreviousNext
Back to top
March 2001
Volume 10, Issue 3
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Association between Polymorphisms in the CYP17 and 5α-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Association between Polymorphisms in the CYP17 and 5α-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men
Naomi E. Allen, Matthew S. Forrest and Timothy J. Key
Cancer Epidemiol Biomarkers Prev March 1 2001 (10) (3) 185-189;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Association between Polymorphisms in the CYP17 and 5α-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men
Naomi E. Allen, Matthew S. Forrest and Timothy J. Key
Cancer Epidemiol Biomarkers Prev March 1 2001 (10) (3) 185-189;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement